Japan Approves Dupixent for Chronic Spontaneous Urticaria (CSU) Becoming First in the World to Do So
This makes CSU treatment the sixth approved use globally.
japanese flag © somartin - stock.adobe.com
The Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU), according to today’s Regeneron and Sanofi press release.
CSU is characterized by recurrent and itchy hives often triggered by temperature or pressure on the skin. Both adults and children can be affected but it is twice as common in adult females. It is associated with immune disorders like food allergies and hypothyroidism.
About 110,000 people in Japan aged 12 years and older currently suffer from uncontrolled moderate to severe CSU. In the United States, 1% of the population is affected at any given time.
Dupixent is also used to treat atopic dermatitis and asthma with 800,000 being treated globally.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More
High Sodium Intake Associated to Increased Risk of Severe Atopic Dermatitis
June 20th 2024Researchers who conducted the study, of the Universities of California in San Francisco and Berkley, suggest that cutting down on sodium could be a more cost-effective and low-risk way to help manage AD.
Read More
Highly Contagious and Hard-to-Treat Fungal Skin Infections Are Emerging, Experts Warn
June 6th 2024Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.
Read More
